Jubilant Ingrevia

702.40
-5.65
(-0.80%)
Market Cap
11,187.90 Cr
EPS
11.56
PE Ratio
44.53
Dividend Yield
0.71 %
Industry
Chemicals
52 Week High
885.00
52 Week Low
462.30
PB Ratio
3.82
Debt to Equity
0.13
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+66.67 %
+66.67 %
Hold
Hold+33.33 %
+33.33 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
3,107.20
#1 1,58,047.00
75.43
12,522.60
5.69
#1 1,747
40.49
61.30
2,861.00
84,807.10
67.75
13,221.50
-11.53
1,336
24.61
42.47
3,553.30
39,033.00
71.54
4,387.70
-25.09
435
89.11
26.64
2,027.30
27,651.00
#1 39.67
7,757.90
-3.26
811
-20.24
50.34
472.40
23,321.50
41.99
4,664.30
#1 10.33
555
34.98
58.50
5,212.60
22,563.10
49.22
#1 13,843.30
-
563
-83.27
64.70
4,261.20
21,124.30
73.23
2,120.90
0.37
271
34.94
45.48
7,136.50
21,011.10
43.35
4,783.90
-13.69
324
#1 121.26
65.91
1,843.40
19,109.70
47.12
1,938.80
-8.77
323
18.04
60.54
469.25
17,011.20
51.64
6,380.70
-3.61
417
-27.27
57.08

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
-13.21 %
Net Income Growth
-40.52 %
Cash Flow Change
-7.02 %
ROE
-42.06 %
ROCE
-37.57 %
EBITDA Margin (Avg.)
-9.44 %

Quarterly Financial Results

Quarterly Financials
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
0
682
1,145
1,224
1,292
1,285
1,170
1,306
1,160
1,139
1,077
1,020
969
1,070
1,020
1,040
1,056
1,047
Expenses
0
580
863
1,027
1,074
1,153
1,025
1,151
1,007
1,043
959
902
871
983
915
921
919
905
EBITDA
0
102
281
197
219
132
145
156
153
96
119
118
98
87
105
119
137
142
Operating Profit %
0 %
15 %
24 %
16 %
16 %
10 %
12 %
11 %
13 %
8 %
10 %
11 %
9 %
7 %
9 %
11 %
12 %
13 %
Depreciation
0
22
32
31
30
31
31
31
30
30
32
34
34
36
39
40
40
39
Interest
0
7
13
7
5
6
4
5
7
6
12
13
15
14
14
15
12
14
Profit Before Tax
0
77
243
165
187
115
116
124
122
76
81
80
55
51
66
80
96
102
Tax
0
23
75
54
58
46
36
40
30
23
24
22
17
22
17
21
26
28
Net Profit
0
54
168
111
129
69
79
84
92
52
58
58
39
29
49
59
69
74
EPS in ₹
0.00
5.20
10.58
6.97
8.12
4.31
4.99
5.31
5.75
3.29
3.63
3.64
2.44
1.85
3.08
3.73
4.39
4.69

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
Total Assets
0
3,379
3,797
4,259
4,732
Fixed Assets
0
1,805
1,798
1,846
2,539
Current Assets
0
1,424
1,765
1,818
1,780
Capital Work in Progress
0
65
174
525
331
Investments
0
50
6
8
16
Other Assets
0
1,458
1,819
1,880
1,846
Total Liabilities
0
3,379
3,797
4,259
4,732
Current Liabilities
0
894
1,053
1,180
1,286
Non Current Liabilities
0
561
311
413
708
Total Equity
-0
1,923
2,433
2,666
2,738
Reserve & Surplus
-0
1,907
2,417
2,650
2,722
Share Capital
0
16
16
16
16

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
Net Cash Flow
0
73
-36
35
6
Investing Activities
0
33
-71
-469
-568
Operating Activities
0
112
453
463
430
Financing Activities
0
-72
-418
42
144

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
50.68 %
50.92 %
50.92 %
51.03 %
51.10 %
51.47 %
51.47 %
51.47 %
51.47 %
51.47 %
51.47 %
51.47 %
51.47 %
51.47 %
51.47 %
51.47 %
51.47 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
6.35 %
6.58 %
6.55 %
7.22 %
6.89 %
7.12 %
DIIs
0.83 %
0.96 %
0.32 %
0.14 %
0.15 %
0.17 %
1.38 %
4.90 %
5.98 %
6.73 %
8.21 %
11.18 %
13.61 %
14.09 %
15.47 %
15.99 %
15.92 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.76 %
21.30 %
27.18 %
26.23 %
27.31 %
27.61 %
26.71 %
25.75 %
25.72 %
26.13 %
24.11 %
22.74 %
20.63 %
20.57 %
19.47 %
19.17 %
19.13 %
Others
31.74 %
26.82 %
21.58 %
22.60 %
21.43 %
20.75 %
20.44 %
17.87 %
16.83 %
15.66 %
16.20 %
8.26 %
7.71 %
7.32 %
6.36 %
6.47 %
6.36 %
No of Share Holders
60,038
95,235
1,49,939
1,81,847
1,91,477
1,93,858
1,95,704
1,86,895
1,85,062
1,86,294
1,73,533
1,62,202
1,50,388
1,42,736
1,25,367
1,24,830
1,20,406

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.35 5 5 5 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.08 1.39 1.1 0.77 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 696.10 718.00
03 Feb 2025 DIVIDEND Dividend
₹ 2.50 /share
03 Feb 2025 659.30 697.65
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 711.10 659.30
22 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 Oct 2024 732.20 731.40
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Aug 2024 610.10 642.85
02 Aug 2024 DIVIDEND Dividend
₹ 2.50 /share
02 Aug 2024 519.65 612.55
09 Feb 2024 DIVIDEND Dividend
₹ 2.50 /share
09 Feb 2024 460.65 436.55
10 Aug 2023 DIVIDEND Dividend
₹ 2.50 /share
10 Aug 2023 422.00 433.05
10 Feb 2023 DIVIDEND Dividend
₹ 2.50 /share
10 Feb 2023 472.90 472.65
24 Aug 2022 DIVIDEND Dividend
₹ 2.50 /share
23 Aug 2022 464.15 476.15
11 Feb 2022 DIVIDEND Dividend
₹ 2.50 /share
10 Feb 2022 572.25 567.85
06 Aug 2021 DIVIDEND Dividend
₹ 0.35 /share
05 Aug 2021 571.85 610.15
01 Feb 2021 CHANGE OF NAME Change Of Name
NA
01 Feb 2021 0.00 0.00

Announcements

Compliances-Reg.24(A)-Annual Secretarial Compliance1 day ago
Response To BSE In Reference To Mail Received On May 29 20251 day ago
Clarification sought from Jubilant Ingrevia Ltd1 day ago
Announcement under Regulation 30 (LODR)-Retirement6 days ago
Intimation Of Record Date For Maturity Of Commercial Papers 7 days ago
Announcement under Regulation 30 (LODR)-Issue of Securities7 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 13, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
Intimation Of Record Date - Friday July 25 2025May 13, 2025
Corporate Action-Board approves DividendMay 13, 2025
Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31 2025May 13, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 13 2025May 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 28, 2025
Board Meeting Intimation for 1. Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31 2025; And 2. Recommendation Of Final Dividend For The Financial Year Ended March 31 2025 Ifany.Apr 28, 2025
Updates On AcquisitionApr 25, 2025
Update On Material Development About The Disclosure Made On February 25 2025Apr 20, 2025
Commercial Paper Proceeds Utilisation Certificate For The Quarter Ended March 31 2025Apr 14, 2025
Intimation Of Record Date For Maturity Of Commercial PaperApr 08, 2025
Announcement under Regulation 30 (LODR)-Issue of SecuritiesApr 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 31, 2025
Addendum To Trust Deed Of Jubilant Ingrevia Employees Welfare TrustMar 27, 2025
Certificate Under Chapter XVII Of SEBI Operational Circular Dated 22Nd May 2024 As AmendedMar 27, 2025
Intimation of Repayment of Commercial Paper (CP)Mar 27, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 28, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 28, 2025
Intimation of Repayment of Commercial Paper (CP)Feb 25, 2025
Certificate Under Chapter XVII Of SEBI Operational Circular Dated 22Nd May 2024 Feb 25, 2025
Rumour verification - Regulation 30(11)Feb 25, 2025
Intimation Of Redemption Of Commercial PaperFeb 24, 2025
Certificate Under Chapter XVII Of SEBI Operational Circular Dated 22Nd May 2024 As Amended Feb 24, 2025
Disclosure Of Material Event Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Feb 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 03, 2025
Intimation Of Record Date For Maturity Of Commercial PaperJan 31, 2025
Announcement under Regulation 30 (LODR)-Issue of SecuritiesJan 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 29, 2025
Integrated Filing (Financial)Jan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 28, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesJan 28, 2025
Corporate Action - Fixes Record Date For Interim Dividend As February 03 2025Jan 28, 2025

Technical Indicators

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
DSP Regular Savings Fund Direct-Growth
7466
0.29%
-0.26%
-0.58%
Apr 2025
UTI Small Cap Fund Direct - Growth
1091633
1.66%
0.23%
0.31%
Apr 2025
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
30336
0.61%
0.16%
0.61%
Apr 2025
DSP Top 100 Equity Direct Plan-Growth
1082115
1.24%
-0.15%
-0.24%
Apr 2025
Edelweiss Small Cap Fund Direct - Growth
1424301
2.16%
-0.12%
-0.20%
Apr 2025
ITI ELSS Tax Saver Fund Direct - Growth
6549
0.11%
0.11%
0.11%
Apr 2025
Bandhan Innovation Fund Direct-Growth
473104
2.12%
-0.10%
-0.10%
Apr 2025
DSP Multicap Fund Direct - Growth
439283
1.36%
-0.10%
-0.15%
Apr 2025
Motilal Oswal Multi Cap Fund Direct - Growth
153034
0.28%
0.07%
-1.42%
Apr 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0
0.00%
-0.07%
-0.07%
Apr 2025
DSP Midcap Direct Plan-Growth
4469774
1.63%
-0.06%
-0.10%
Apr 2025
Bandhan Aggressive Hybrid Fund Direct-Growth
153651
1.17%
0.06%
0.05%
Apr 2025
Franklin India Smaller Companies Fund Direct-Growth
1600000
0.82%
-0.05%
-0.06%
Apr 2025
DSP Small Cap Direct Plan-Growth
7800000
3.51%
-0.04%
-0.17%
Apr 2025
DSP Equity Savings Fund Direct-Growth
214476
0.51%
-0.04%
-0.02%
Apr 2025
Bandhan Small Cap Fund Direct-Growth
520374
0.33%
-0.03%
-0.05%
Apr 2025
Axis Momentum Fund Direct - Growth
101386
0.50%
-0.03%
-0.04%
Apr 2025
DSP India T.I.G.E.R. (The Infrastructure Growth and Economic Reforms Fund) Direct-Growth
901809
1.17%
-0.03%
-0.07%
Apr 2025
Edelweiss Large & Mid Cap Direct Plan-Growth
248533
0.43%
-0.02%
-0.03%
Apr 2025
Bandhan Large Cap Fund Direct-Growth
151815
0.53%
0.02%
0.53%
Apr 2025
Edelweiss ELSS Tax Saver Fund Direct -Growth
26719
0.43%
-0.02%
-0.04%
Apr 2025
Bandhan Business Cycle Fund Direct-Growth
23927
0.09%
-0.01%
-0.01%
Apr 2025
Axis Small Cap Fund Direct-Growth
616671
0.17%
-0.01%
0.17%
Apr 2025
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
2144
0.27%
-0.01%
-0.03%
Apr 2025
SBI Nifty Smallcap 250 Index Fund Direct - Growth
54449
0.27%
-0.01%
-0.03%
Apr 2025

About Jubilant Ingrevia

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider. Incorporated in 2019, the company serves Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It operates through three core segments: Speciality Chemicals, Nutrition and Health Solutions, and Life Science Chemicals. The company manufactures and supplies speciality intermediates, nutrition & health solutions, and life science chemicals through five facilities in India. Jubilant Ingrevia is the global largest producer of Niacinamide and among the top two manufacturers of Vitamin B3 globally. It serves over 1400 customers in more than 60 countries and offers custom research and manufacturing services. The company is part of the Jubilant Bhartia Group and became a separate entity following a demerger from Jubilant Pharmova Limited in 2021.
Chairperson NameShyam S Bhartia